PreSize Diagnostic medical device software for increased precision in advance selection of best surgical scenario for every patient at point of diagnosis

我们开发了PreSize医疗设备软件：这是一种新颖的临床决策支持解决方案，可以帮助外科医生在开始挽救生命的手术之前，通过真实的实时模拟来计划和排练植入物在脑血管中的放置。使用尖端的计算模型，我们充分利用患者成像和设备力学来准确预测每个患者血管解剖内的设备行为。这使得临床医生可以为每个病人选择最好的设备，减少并发症和医院/社会的手术成本。该项目将扩大/增强PreSize的能力，为更多患者提供从诊断到治疗的关键临床决策支持。我们将为临床医生提供前所未有的能力，并从根本上改变动脉瘤护理途径的潜力。具体来说，除了PreSize目前使用的（3D） DSA**（昂贵、有创成像，但质量显著提高，用于指导手术过程中植入物的放置）之外，我们还将推进已经具有突破性的PreSize，以支持诊断**CTA**扫描（快速、廉价、微创成像，用于大多数疑似动脉瘤患者）。**拟议的PreSize诊断**在整个护理过程中增加了精准医疗，而不仅仅是在手术当天，支持针对患者的治疗分层/计划，并通过前所未有的技术支持帮助临床医生为手术当天做好最好的准备（适应最佳植入物选择并提供最佳手术结果）。这些技术进步的最终目标是减少患者的痛苦，最大限度地降低医疗成本，并优化/标准化护理。我们是一家屡获殊荣的初创公司，旨在将这项新技术引入医院。我们拥有一支由工程、软件、商业、法律和监管专家组成的强大团队，之前得到了IUK和NIHR的支持，并得到了皇家工程院的持续支持。我们的奖项包括：* NHS创新奖2017年*“2018年最佳医疗保健初创企业”(WIRED)*生物医学工程创新奖2021年“突破性工作，导致支持医疗干预的新技术”** *英国的“女性创新”奖2023年**为“英国50位领先的女性企业家改变游戏规则的想法之一”我们被选为数字健康。是飞利浦医疗保健加速器在全球选定的6家初创企业之一。我们在《福布斯》、《连线》、《泰晤士报》、《金融时报》、《每日电讯报》等媒体上都有特写。最近，PreSize在**BBC点击**科技展上被捕获（2023年2月3日，BBC iPlayer）。我们的目标是将Oxford Heartbeat发展成为临床决策支持工具的领先提供商，促进英国经济及其在医疗保健领域的国际领导地位，改善所有人的医疗保健，并定义未来的医学。

We have developed PreSize medical device software: a novel clinical decision-support solution that helps surgeons plan and rehearse implant placements inside brain blood vessels with realistic, real-time simulations right before starting life-saving surgery. Using cutting-edge computational modelling, we make best use of patient imaging and device mechanics to accurately predict device behaviour inside each patient's vessel anatomy. This allows clinicians to select the best device for every patient, reducing complications and cost of surgeries for hospitals/society.This project will extend/increase PreSize's power to support crucial clinical decision-making for more patients, across their journey from diagnosis to treatment. We will provide never-before-seen capabilities to clinicians and potential for aneurysm care pathways to be radically transformed. Specifically, we will advance the already ground-breaking PreSize to support diagnostic **CTA** scans(rapid, inexpensive, minimally-invasive imaging used for most patients suspected of aneurysm) in addition to (3D)**DSA** that PreSize currently uses(expensive, invasive imaging, but of significantly higher quality; used to guide placement of implant during procedure).**Proposed PreSize Diagnostic** adds Precision Medicine throughout the care pathway instead of only on surgery day, supporting patient-specific treatment stratification/planning and helping clinicians best prepare for surgery day (accommodating best implant choices and delivering best surgical outcomes) with unprecedented technological support. These technological advancements ultimately aim to reduce patient suffering, minimise healthcare costs, and optimise/standardise care.We are an award-winning start-up created to bring this novel technology to hospitals. With a strong team of engineering, software, commercial, legal and regulatory experts, we have been previously supported by IUK and NIHR and receive ongoing support from The Royal Academy of Engineering. Our awards include:* NHS Innovation Award 2017* "Best Healthcare Start-up of 2018" (WIRED)* BioMedEng Innovation Prize 2021 for 'ground-breaking work which has led to new technologies that support medical interventions'* **IUK's 'Women in Innovation' Award 2023** for 'one of 50 of the UK's leading women entrepreneurs for game-changing ideas'We were selected for the DigitalHealth.London Accelerator programme, and were one of 6 startups selected globally by Philips Healthcare Accelerator. We have featured in the general press, e.g., Forbes, WIRED, The Times, Financial Times, The Telegraph, etc. Most recently, PreSize was captured in action in the **BBC Click** tech show (February 3, 2023, BBC iPlayer).We aim to grow Oxford Heartbeat to become the leading provider of clinical decision-support tools, to boost the UK economy and its international leadership in healthcare, to improve healthcare for all, and define the medicine of tomorrow.